Compare Inovio Pharmaceuticals Inc (INO) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.92. The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SJNK | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Sector/Thematic |
52-Week High | $2.87 | $25.63 |
52-Week Low | $1.05 | $24.75 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SJNK trades at $24.92 with no price change in the last 24 hours, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend payments with recent distributions of $0.14-$0.15 per share. Current technical analysis indicates bearish momentum with key support and resistance clustered around $25 levels.
The short-term high-yield bond ETF faces headwinds from potential yield normalization after benefiting from falling rates. Analyst sentiment appears cautious with recent bearish ratings citing exhausted tailwinds. Key risks include interest rate sensitivity and credit spread volatility in the junk bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
